• 1
    Fernández J, Navasa M, Gómez J, Colmenero J, Vila J, Arroyo V, Rodés J. Bacterial infections in cirrhosis: epidemiologicalchanges with invasive procedures and norfloxacin prophylaxis. HEPATOLOGY 2002; 35: 140-148.
  • 2
    Yoshida H, Hamada T, Inuzuka S, Ueno T, Sata M, Tanikawa K. Bacterial infection in cirrhosis, with and without hepatocellular carcinoma. Am J Gastroenterol 1993; 88: 2067-2071.
  • 3
    Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in cirrhosis. HEPATOLOGY 2009; 50: 2022-2033.
  • 4
    Arvaniti V, D'Amcio G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139: 1246-1256.
  • 5
    Foreman MG, Mannino DM, Moss M. Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey. Chest 2003; 124: 1016-1020.
  • 6
    Felisart J, Rimola A, Arroyo V, Perez-Ayuso RM, Quintero E, Gines P, et al. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. HEPATOLOGY 1985; 5: 457-462.
  • 7
    Rimola A, Garcia-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, et al. Diagnosis, treatment, and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatol 2000; 32: 142-153.
  • 8
    Runyon BA; AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. HEPATOLOGY 2009; 49: 2087-2107.
  • 9
    European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417.
  • 10
    Fernández J, Navasa N, Planas R, Montoliu S, Monfort D, Soriano G, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818-824.
  • 11
    Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008; 28: 26-42.
  • 12
    Titó Ll, Rimola A, Ginès P, Llach J, Arroyo V, Rodés J. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. HEPATOLOGY 1988; 8: 27-31.
  • 13
    Bernard, B., Grangé, J. D., Khac, E. N., Amiot, X., Opolon, P., Poynard, T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. HEPATOLOGY 1999; 29: 1655-1661.
  • 14
    Fernández J, Ruiz del Arbol L, Gómez C, Durandez R, Serradilla R, Guarner C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006; 131: 1049-1056.
  • 15
    Ginès P, Rimola A, Planas R, Vargas V, Marco F, Almela M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. HEPATOLOGY 1990; 12: 716-724.
  • 16
    Campillo B, Dupeyron C, Richardet JP, Mangeney N, Leluan G. Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. Clin Infect Dis 1998; 26: 1066-1070.
  • 17
    Park YH, Lee HC, Song HG, Jung S, Ryu SH, Shin JW, et al. Recent increase in antibiotic-resistant microorganisms in patients with spontaneous bacterial peritonitis adversely affects the clinical outcome in Korea. J Gastroenterol Hepatol 2003; 18: 927-933.
  • 18
    Song KH, Jeon JH, Park WB, Park SW, Kim HB, Oh MD, et al. Clinical outcomes of spontaneous bacterial peritonitis due to extended spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: a retrospective matched case-control study. BMC Infect Dis 2009; 9: 41-46.
  • 19
    Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Oh MD, et al. Clinical outcome of bacteremic spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Korean J Intern Med 2004; 19: 160-164.
  • 20
    Song JY, Jung SJ, Park CW, Sohn JW, Kim WJ, Kim MJ, et al. Prognostic significance of infection acquisition sites in spontaneous bacterial peritonitis: nosocomial versus community acquired. J Korean Med Sci 2006; 21: 666-671.
  • 21
    Cheong HS, Kang C, Lee JA, Moon SY, Joung MK, Chung DR, et al. Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis. CID 2009; 48: 1230-1236.
  • 22
    Merli M, Lucidi C, Giannelli V, Giusto M, Riggio O, Falcone M, et al. Cirrhotic patients are at risk for HCA bacterial infections. Clin Gastroenterol Hepatol 2010; 8: 979-985.
  • 23
    Falagas ME, Karageorgopoulos DE. Extended-spectrum β-lactamase-producing organisms. J Hosp Infect 2009; 73: 345-354.
  • 24
    Stein GE. Antimicrobial resistance in the hospital setting: impact, trends, and infection control measures. Parmacotherapy 2005; 25: 44S-54S.
  • 25
    Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of Extended-spectrum β-lactamase production in nosocomial infections. Ann Intern Med 2004; 140: 26-32.
  • 26
    Depuydt PO, Vandijck DM, Bekaert MA, Decruyenaere JM, Blot SI, Vogelaers DP, et al. Determinants and impact of multidrug antibiotic resistance in pathogens causing ventilator-associated-pneumonia. Crit Care 2008; 12: R142.
  • 27
    Soriano G, Castellote J, Alvarez C, Girbau A, Gordillo J, Baliellas C, et al. Secondary bacterial peritonitis in cirrhosis: a retrospective study of clinical and analytical characteristics, diagnosis, and management. J Hepatol 2010; 52: 39-44.
  • 28
    Stamm WE. Measurement of pyuria and its relation to bacteriuria. Am J Med 1983; 28; 75: 53-58.
  • 29
    Mandell GL, Bennet JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2010.
  • 30
    Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, et al. Health care—associated bloodstream infections in adults: a reason to change the accepted definition of CA infections. Ann Intern Med 2002; 137: 791-797.
  • 31
    Valenti WM, Chiarello LA. Overview of hospital infection control and nosocomial infections. In: Resse RE, Douglas RG, Jr., eds. A Practical Approach to Infectious Diseases. Boston, MA: Lippincott; 1986: 545-555.
  • 32
    Performance Standards for Antimicrobial Susceptibility Testing. Fifteenth International Supplement. Wayne, PA: Clinical and Laboratory Performance Institute/NCCLS; 2005.
  • 33
    Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. American Thoracic Society; Infectious Diseases Society of America. Am J Respir Crit Care Med 2005; 171: 388-416.
  • 34
    American College of Chest Physicians/Society of Critical Care Medicine. Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874.
  • 35
    Dellinger RP. Cardiovascular management of septic shock. Crit Care Med 2003; 31: 946-955.
  • 36
    Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention, and treatment of the hepatorenal syndrome in cirrhosis. A consensus workshop of the International Ascites Club. Gut 2007; 56: 1310-1318.
  • 37
    Apisarnthanarak A, Bailey TC, Fraser VJ. Duration of stool colonization in patients infected with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. CID 2008; 46: 1322-1323.
  • 38
    Azap OK, Arslan H, Serefhanoğlu K, Colakoğlu S, Erdoğan H, Timurkaynak F, et al. Risk factors for extended-spectrum β-lactamase positivity in uropathogenic Escherichia coli isolated from CA urinary tract infections. Clin Microbiol Infect 2010; 16: 147-151.
  • 39
    Ben-Ami R, Rodríguez-Baño J, Arslan H, Pitout JD, Quentin C, Calbo ES, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009; 49: 682-690.
  • 40
    Rodríguez-Baño J, Picón E, Gijón P, Hernández JR, Ruíz M, Peña C, et al. Community-onset bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: risk factors and prognosis. CID 2010; 50: 40-48.
  • 41
    Rodríguez-Baño J, Picón E, Gijón P, Hernández JR, Cisneros JM, Peña C, et al. Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. J Clin Microbiol 2010; 48: 1726-1731.
  • 42
    Dupeyron C, Mangeney N, Sedrati L, Campillo B, Fouet P, Leluan G. Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. Antimicrob Agents Chemother 1994; 38: 340-344.
  • 43
    Aparicio JR, Such J, Pascual S, Pérez-Mateo M, Plaza J, Arroyo A. Development of QR strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences. J Hepatol 1999; 31: 277-283.
  • 44
    Cereto F, Herranz X, Moreno E, Andreu A, Vergara A, Fontanals D, et al. Role of host and bacterial virulence factors in Escherichia coli spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol 2008; 20: 924-929.
  • 45
    Angeloni S, Leboffe C, Parente A, Venditti M, Giordano A, Merli M, et al. Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice. World J Gastroenterol 2008; 14: 2757-2762.
  • 46
    Yakar T, Güçlü M, Serin E, Aliskan H, Husamettin E. A recent evaluation of empirical cephalosporin treatment and antibiotic resistance of changing bacterial profiles in spontaneous bacterial peritonitis. Dig Dis Sci 2009; 55: 1149-1154.
  • 47
    Umgelter A, Reindl W, Miedaner M, Schmid RM, Huber W. Failure of current antibiotic first-line regimens and mortality in hospitalized patients with spontaneous bacterial peritonitis. Infection 2009; 37: 2-8.
  • 48
    Park WB, Lee KD, Lee CS, Jang HC, Kim HB, Lee HS, et al. Production of C-reactive protein in Escherichia coli-infected patients with liver dysfunction due to liver cirrhosis. Diagn Microbiol Infect Dis 2005; 51: 227-230.
  • 49
    Blot S. Limiting the attributable mortality of nosocomial infection and multidrug resistance in intensive care units. Clin Microbiol Infect 2008; 14: 5-13.